Long-term testosterone treatment during pregnancy does not alter insulin or glucose profile in a sheep model of polycystic ovary syndrome

Abstract Context Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductive-aged women, affecting approximately 5-20% of women of reproductive age. A previous estimate noted that the economic burden of PCOS approximates $3.7 billion annually in 2020 USD when considering only the costs of the initial diagnosis and of reproductive endocrine morbidities, not considering the costs of pregnancy-related and long-term morbidities. Objective To estimate the excess prevalence and economic burden of pregnancy-related and long-term health morbidities attributable to PCOS. Data Sources PubMed, EmBase and Cochrane Library. Study Selection Studies in which the diagnosis of PCOS was consistent with the Rotterdam, National Institutes of Health (NIH), or Androgen Excess & PCOS (AE-PCOS) Society criteria, or that used electronic medical record diagnosis codes, or diagnosis based on histopathologic sampling were eligible for inclusion. Studies that included an outcome of interest and a control group of non-PCOS patients who were matched or controlled for body mass index (BMI) were included. Data Extraction Two investigators working independently extracted data on study characteristics and outcomes. Data Synthesis Data was pooled using random-effects meta-analysis. The I 2statistic was used to assess inter-study heterogeneity. The quality of selected studies was assessed using the Newcastle-Ottawa Scale. Results The additional total healthcare-related economic burden due to pregnancy-related and long-term morbidities associated with PCOS in the United States is estimated to be $4.3 billion annually in 2020 USD. Conclusions Together with our prior analysis, the economic burden of PCOS is estimated at $8 billion annually in 2020 USD.

Download Full-text

Management of polycystic ovary syndrome involves addressing current needs and preventing long-term consequences

Drugs & Therapy Perspectives ◽

10.2165/00042310-200723050-00004 ◽

2007 ◽

Vol 23 (5) ◽

pp. 12-14

Author(s):

&NA;

Keyword(s):

Polycystic Ovary Syndrome ◽

Polycystic Ovary ◽

Ovary Syndrome ◽

Long Term Consequences

Download Full-text

Long-term consequences of polycystic ovary syndrome: Results of a 31 year follow-up study

Human Fertility ◽

10.1080/1464727002000198781 ◽

2000 ◽

Vol 3 (2) ◽

pp. 101-105 ◽

Cited By ~ 170

Author(s):

Sarah Wild ◽

Tracey Pierpoint ◽

Howard Jacobs ◽

Paul McKeigue

Keyword(s):

Polycystic Ovary Syndrome ◽

Polycystic Ovary ◽

Ovary Syndrome ◽

Follow Up Study ◽

Long Term Consequences

Download Full-text

Polycystic ovary syndrome: metabolic aspects

Oxford Textbook of Endocrinology and Diabetes ◽

10.1093/med/9780199235292.003.0857 ◽

2011 ◽

pp. 1235-1239

Author(s):

Richard S. Legro

Keyword(s):

Polycystic Ovary Syndrome ◽

Insulin Action ◽

Polycystic Ovary ◽

Metabolic Abnormalities ◽

Polycystic Ovaries ◽

Ovary Syndrome ◽

Insulin Resistant ◽

The Metabolic Syndrome ◽

Health Disorders

Polycystic ovary syndrome (PCOS) is thought to be primarily a disorder that affects women during their reproductive years. The diagnostic criteria reflect ovarian dysfunction, i.e. hyperandrogenism, anovulation, and polycystic ovaries. However, women with PCOS appear to be uniquely insulin resistant, are frequently obese, and may be at risk for a variety of long-term health disorders including diabetes, cardiovascular disease, and cancers. Although the endocrine and reproductive features of the disorder improve with age, the associated metabolic abnormalities, particularly components of the metabolic syndrome, may actually worsen. This chapter will explore the pathophysiology of aberrant insulin action in women with PCOS, recognition of long-term risks, and preventive strategies.

Download Full-text